Product Name: CK2a1 (70-91)
Product Number: PE-01AQG70
| Size: | 200 µg | Price: | 17.00 | |
| 1 mg | $US | 33.00 | ||
| 5 mg | 90.00 |
Peptide Name: CK2a1 (70-91)
Product Use: Services as a blocking peptide for use with the CK2a (CK2a-1) rabbit polyclonal antibody (Cat. No.: AB-NK041) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic subdomain 3.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LKPVKKKKIKREIKILENLRGGC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2691.35 Da
Peptide Purity Percent after Synthesis and Purification: >50
Product Use: Services as a blocking peptide for use with the CK2a (CK2a-1) rabbit polyclonal antibody (Cat. No.: AB-NK041) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic subdomain 3.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: LKPVKKKKIKREIKILENLRGGC
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2691.35 Da
Peptide Purity Percent after Synthesis and Purification: >50
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: CK2a1 pan-specific antibody (Cat. No.: AB-NK041)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: CK2a1 pan-specific antibody (Cat. No.: AB-NK041)
Scientific Background: CK2a1 (CSNK2A1) is a protein-serine/threonine kinase of the Other group and CK2 family. CK2a1 is activated by the CK2-beta regulatory subunit and also by binding p38a MAPK. CK2 is potently inhibited by heparin. It is involved in various cellular processes, such as cell cycle control, apoptosis, transcription, and viral infection. It can phosphorylate human p53 protein a tS392 with presence of UV irradiation, which may be a potential mechanism for p53 activation by UV irradiation. It also phosphorylates the caspases CASP9 and CASP2, and hence negatively regulates apoptosis. CK2a1 levels are often up-regulated by 2-fold in expression in many human tumours.
© Kinexus Bioinformatics Corporation 2017